Raymond James Upgraded This Biopharma Stock And Sees 44% Upside

  • Raymond James has upgraded NGM Biopharmaceuticals Inc NGM to Strong Buy from Outperform with a price target of $39, up from $27, almost 44% upside.
  • Analyst Steven Seedhouse notes the validation of NGM's C3 antibody mechanism and the large potential opportunity for NGM621 in geographic atrophy (GA). 
  • Seedhouse writes that Phase 3 data for Apellis Pharmaceuticals Inc's APLS pegcetacoplan in GA provide strong evidence that complement inhibition is an active mechanism in GA. 
  • Related Content: Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line.
  • The update makes the large GA market accessible to the few mid-stage clinical complement players with plenty of room for differentiation/optimization, he contends. 
  • Near term, the first-look readout for cancer cachexia agent NGM120 at ESMO next week is a free call option, Seedhouse adds.
  • Price Action: NGM stock is up 13% at $26.39 during the market session on the last check Monday.
Loading...
Loading...
APLS Logo
APLSApellis Pharmaceuticals Inc
$17.205.13%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
8.65
Growth
-
Quality
-
Value
47.86
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...